Patent US4428962A successfully refreshed from Google Patents.
US4428962A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Indoles in treatment of peptic ulcers
Assignee: Merck Sharp & Dohme LLC
•
Filing: 1981-10-30
•
Granted: 1984-01-31
•
Expires: 2001-10-30
Abstract
Abstract There are disclosed herein certain indole derivatives which are useful in the treatment of peptic ulcer diseases.
Inventors
- 👤 James A. Bristol
- 👤 Chester Puchalski
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 22:12
CPC Classifications
C; C07; C07D; C07D209/00; C07D209/02; C07D209/04; C07D209/08
Claims Analysis
Total Claims: 34
Claim 1
Independent Claim
40 words
A compound represented by formula: ##STR13## and pharmaceutically acceptable salts thereof, wherein R' 1 represents hydrogen or methyl; R' 2 represents methyl and R' 3 represents methyl, cyanomethyl, or amino; X' represents hydrogen; and Y' represents phenylmethoxy, 2-phenylethyl or 3-phenyl-1-propenyl.
Claim 2
Dependent Claim
40 words
A compound represented by formula: ##STR13## and pharmaceutically acceptable salts thereof, wherein R' 1 represents hydrogen or methyl; R' 2 represents methyl and R' 3 represents methyl, cyanomethyl, or amino; X' represents hydrogen; and Y' represents phenylmethoxy, 2-phenylethyl or 3-phenyl-1-propenyl.
Claim 3
Dependent Claim
24 words
A compound of claim 1 wherein R' 1 , R' 2 , and R' 3 are each methyl and Y' is phenylmethoxy, i.e. 1,2,3-trimethyl-7-phenylmethoxyindole.
Claim 4
Dependent Claim
24 words
A compound of claim 1 wherein R' 1 is hydrogen, R' 2 and R' 3 are each methyl and Y' is phenylmethoxy, i.e. 2,3-dimethyl-7-phenylmethoxyindole.
Claim 5
Dependent Claim
24 words
A compound of claim 1 wherein R' 1 is hydrogen, R' 2 is methyl, R' 3 is amino and Y' is phenylmethoxy, i.e. 2-methyl-3-amino-7-phenylmethoxyindole.
Claim 6
Dependent Claim
24 words
A compound of claim 1 wherein R' 1 is hydrogen, R' 2 and R' 3 are each methyl and Y' is 2-phenylethyl, i.e. 2,3-dimethyl-7-(2-phenylethyl)indole.
Claim 7
Dependent Claim
24 words
A compound of claim 1 wherein R' 1 is hydrogen, R' 2 and R' 3 are each methyl and Y' is 3-phenyl-1-propenyl, i.e. 2,3-dimethyl-7-(3-phenyl-1-propenyl)indole.
Claim 8
Dependent Claim
24 words
A compound of claim 1 wherein R' 1 is hydrogen, R' 2 is methyl, R' 3 is cyanomethyl and Y' is 2-phenylethyl, i.e. 2-methyl-3-cyanomethyl-7-(2-phenylethyl)indole.
Claim 9
Dependent Claim
24 words
A compound of claim 1 wherein R' 1 is hydrogen, R' 2 is methyl, R' 3 is amino and Y' is 2-phenylethyl, i.e. 2-methyl-3-amino-7-(2-phenylethyl)indole.
Claim 10
Dependent Claim
24 words
A compound of claim 1 wherein R' 1 is hydrogen, R' 2 is methyl R' 3 is cyanomethyl and Y' is 3-phenyl-1-propenyl, i.e. 2-methyl-3-cyanomethyl-7-(3-phenyl-1-propenyl)indole.
Claim 11
Dependent Claim
24 words
A compound of claim 1 wherein R' 1 is hydrogen, R' 2 is methyl, R' 3 is amino, and Y' is 3-phenyl-1-propenyl, i.e. 2-methyl-3-amino-7-(3-phenyl-1-propenyl)indole.
Claim 12
Dependent Claim
34 words
A method for the treatment of the symptoms of peptic ulcer disease in mammals, which comprises administering to a mammal having peptic ulcer disease a therapeutically effective quantity of a compound of claim 1.
Claim 13
Dependent Claim
29 words
A method for the treatment of gastric ulcers in mammals which comprises administering to a mammal having gastric ulcers a therapeutically effective quantity of a compound of claim 1.
Claim 14
Dependent Claim
29 words
A method for the treatment of duodenal ulcers in mammals which comprises administering to a mammal having duodenal ulcers a therapeutically effective quantity of a compound of claim 1.
Claim 15
Dependent Claim
21 words
A method of claim 11 which comprises administering to a mammal having peptic ulcer disease, a therapeutically effecive quantity of 1,2,3-trimethyl-7-phenylmethoxyindole.
Claim 16
Dependent Claim
37 words
A pharmaceutical formulation for use in the treatment of ulcers which comprises a compound of claim 1 in a therapeutically effective amount sufficient to alleviate the symptoms of peptic ulcer disease together with a pharmaceutically acceptable carrier.
Claim 17
Dependent Claim
20 words
A pharmaceutical formulation of claim 15 which comprises a therapeutically effective amount of 1,2,3-trimethyl-7-phenylmethoxyindole together with a pharmaceutically acceptable carrier.
Claim 18
Dependent Claim
10 words
A pharmaceutical formulation of claim 15 suitable for oral administration.
Claim 19
Dependent Claim
21 words
A method of claim 11 which comprises administering to a mammal having peptic ulcer disease, a therapeutically effective quantity of 2,3-dimethyl-7-phenylmethoxyindole.
Claim 20
Dependent Claim
21 words
A method of claim 11 which comprises administering to a mammal having peptic ulcer disease, a therapeutically effective quantity of 2-methyl-3-amino-7-phenylmethoxyindole.
Claim 21
Dependent Claim
21 words
A method of claim 11 which comprises administering to a mammal having peptic ulcer disease, a therapeutically effective quantity of 2,3-dimethyl-7-(2-phenylethyl)indole.
Claim 22
Dependent Claim
21 words
A method of claim 11 which comprises administering to a mammal having peptic ulcer disease, a therapeutically effective quantity of 2,3-dimethyl-7-(3-phenyl-1-propenyl)indole.
Claim 23
Dependent Claim
21 words
A method of claim 11 which comprises administering to a mammal having peptic ulcer disease, a therapeutically effective quantity of 2-methyl-3-cyanomethyl-7-(2-phenylethyl)indole.
Claim 24
Dependent Claim
21 words
A method of claim 11 which comprises administering to a mammal having peptic ulcer disease, a therapeutically effective quantity of 2-methyl-3-amino-7-(2-phenylethyl)indole.
Claim 25
Dependent Claim
21 words
A method of claim 11 which comprises administering to a mammal having peptic ulcer disease, a therapeutically effective quantity of 2-methyl-3-cyanomethyl-7-(3-phenyl-1-propenyl)indole.
Claim 26
Dependent Claim
21 words
A method of claim 11 which comprises administering to a mammal having peptic ulcer disease, a therapeutically effective quantity of 2-methyl-3-amino-7-(3-phenyl-1-propenyl)indole.
Claim 27
Dependent Claim
20 words
A pharmaceutical formulation of claim 15 which comprises a therapeutically effective amount of 2,3-dimethyl-7-phenylmethoxyindole together with a pharmaceutically acceptable carrier.
Claim 28
Dependent Claim
20 words
A pharmaceutical formulation of claim 15 which comprises a therapeutically effective amount of 2-methyl-3-amino-7-phenylmethoxyindole together with a pharmaceutically acceptable carrier.
Claim 29
Dependent Claim
20 words
A pharmaceutical formulation of claim 15 which comprises a therapeutically effective amount of 2,3-dimethyl-7-(2-phenylethyl)-indole together with a pharmaceutically acceptable carrier.
Claim 30
Dependent Claim
20 words
A pharmaceutical formulation of claim 15 which comprises a therapeutically effective amount of 2,3-dimethyl-7-(3-phenyl-1-propenyl)indole together with a pharmaceutically acceptable carrier.
Claim 31
Dependent Claim
20 words
A pharmaceutical formulation of claim 15 which comprises a therapeutically effective amount of 2-methyl-3-cyanomethyl-7-(2-phenylethyl)indole together with a pharmaceutically acceptable carrier.
Claim 32
Dependent Claim
20 words
A pharmaceutical formulation of claim 15 which comprises a therapeutically effective amount of 2-methyl-3-amino-7-(2-phenylethyl)indole together with a pharmaceutically acceptable carrier.
Claim 33
Dependent Claim
20 words
A pharmaceutical formulation of claim 15 which comprises a therapeutically effective amount of 2-methyl-3-cyanomethyl-7-(3-phenyl-1-propenyl)indole together with a pharmaceutically acceptable carrier.
Claim 34
Dependent Claim
20 words
A pharmaceutical formulation of claim 15 which comprises a therapeutically effective amount of 2-methyl-3-amino-7-(3-phenyl-1-propenyl)indole together with a pharmaceutically acceptable carrier.
References Cited (Backward Citations)
US3076814A
Cited
US3072530A
Cited
US3297717A
Cited
US4021448A
Cited
DE2727829A1
Cited
GB2035310B
Cited
US4285962A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-01-30 | 1987-08-01 | 1988-01-31 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-01-30 | 1991-08-01 | 1992-01-31 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-01-30 | 1995-08-01 | 1996-01-31 | $7700.00 | Window Closed / Lapsed |